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REVIEW ARTICLE OPEN
Daytime symptoms of chronic obstructive pulmonary
disease: a systematic review
Ioanna Tsiligianni1✉ and Janwillem W. H. Kocks 2,3,4
There is no single source of compiled data on symptoms experienced by patients with chronic obstructive pulmonary disease
(COPD) when awake and active throughout the day. The aim of this systematic review was to evaluate the prevalence, variability,
and burden (i.e., bothersomeness and/or intensity), and the impact of daytime COPD symptoms on other outcomes. The review
also evaluated the impact of interventions and the measures/tools used to assess daytime COPD symptoms in patients. A
systematic literature search was conducted using the primary search terms “COPD”, “symptoms”, and “daytime” in EMBASE®,
MEDLINE®, MEDLINE® In-Process, and CENTRAL in 2016, followed by an additional search in 2018 to capture any new literature that
was published since the last search. Fifty-six articles were included in the review. The accumulated evidence indicated that the
symptomatic burden of COPD appears greatest in the morning, particularly upon waking, and that these morning symptoms have a
substantial impact on patients’ ability to function normally through the day; they also worsen quality of life. A wide variety of tools
were used to evaluate symptoms across the studies. The literature also confirmed the importance of pharmacotherapy in the
management of daytime COPD symptoms, and in helping normalize daily functioning. More research is needed to better
understand how COPD symptoms impact daily functioning and to evaluate COPD symptoms at well-defined periods throughout
the day, using validated and uniform measures/tools. This will help clinicians to better define patients’ needs and take appropriate
action.
npj Primary Care Respiratory Medicine            (2020) 30:6 ; https://doi.org/10.1038/s41533-020-0163-5
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a common
disorder characterized by persistent respiratory symptoms and
airflow limitation, and is associated with significant morbidity and
mortality.1 In 2012, more than 3 million people died of COPD,
accounting for 6% of all deaths globally, and projections suggest
that COPD will be the third leading cause of death in the world by
2020.1 The primary symptoms of COPD are breathlessness, cough,
and increased sputum; many patients also experience wheezing
and chest tightness or congestion, the latter particularly at times
of exertion.1 Other secondary symptoms and related comorbid-
ities include sleep disorders/disturbances and associated daytime
sleepiness,2,3 increased anxiety and/or depression,4,5 and in severe
and very severe cases, fatigue, weight loss, and anorexia.6
Over the past 30 years, studies have recognized that the
presence of variations in circadian and diurnal lung function
generally coincide with exacerbations in patients with COPD.7–11
The prevalence and/or burden of COPD symptoms have been
shown to reflect this circadian and diurnal variability in their
tendency to fluctuate over time throughout the day and night.4,12–14
Moreover, temporal symptom spikes, especially those occurring in
the early morning and late at night, have been associated with
some of the aforementioned secondary symptoms or comorbid-
ities (e.g., sleep disturbance and increased anxiety or depression4).
These spikes have also been linked with worse overall health
status4,15,16 and reduced ability to complete normal daily
activities.15,17
The published literature on COPD is extensive; however, there is
substantial heterogeneity in the results reporting on the circadian
and diurnal variability of COPD symptoms. A nonsystematic review
article evaluating variability of COPD symptoms found that
symptoms are variable over time, and can change with the
seasons, within a week, and even over the same day.18 Moreover,
comprehensive reviews looking at symptoms of COPD at specific
time points during the day or night have provided useful insight
that morning is the worst time of day for patients;19–21 however,
there remains no single source of compiled data on symptoms
experienced throughout the day, when the patient is awake and
active. On this basis, we conducted a systematic literature review
to inform on the current evidence regarding the burden of
daytime symptoms of COPD. Primary objectives were to evaluate
the following: (1) the prevalence, variability, and relative burden
(i.e., bothersomeness and/or intensity) of daytime COPD symp-
toms; (2) the impact of daytime COPD symptoms on other
outcomes (e.g., daily-life activities, health status, quality of life
(QoL), and exacerbations); (3) the impact of interventions used to
treat daytime symptoms, including pharmacotherapy; and (4) the
measures and tools used to assess daytime COPD symptoms.
METHODS
A systematic literature review was conducted in accordance with
the principles recommended in the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement.22 The
prespecified protocol can be found in the Supplementary File.
Literature searches
Four electronic biomedical literature databases (EMBASE®, MED-
LINE®, MEDLINE® In-Process, and CENTRAL) were reviewed in
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September 2016. In order to keep the findings up to date, an
additional search was performed in June 2018 to capture any new
literature that had been published since September 2016. Primary
search terms were “COPD”, “symptoms”, and “daytime”; these
were also expanded to include all recognized variations and
subheadings. Searches were limited to articles for which full-text
publications were available in English. Articles in other languages
were excluded. Electronic searches were supplemented by manual
searching of the reference lists and bibliographies of relevant
systematic reviews and study publications. The detailed search
strategies are provided in Supplementary Tables 1–3.
Study selection
Titles and abstracts were initially examined for possible inclusion
by two independent reviewers. A second eligibility screening—of
the articles that were full-text—was then conducted by a further
two independent reviewers. Any discrepancies between the
decisions of the two reviewers at both stages were resolved by
a third independent reviewer. The detailed selection criteria were
in line with Patient, Intervention, Comparator, Outcomes, and
Study Design (PICOS) and PRISMA guidelines, and are provided in
Table 1.
Data extraction and analysis
Data relating to study design, patient population characteristics,
and outcomes of interest were extracted from abstracts or full-text
articles by a reviewer into a standardized data extraction form.
Each form was then checked by two independent reviewers. Any
discrepancies were resolved through discussion. Data from the
final data extraction forms were tabulated and are discussed in
this review in a purely descriptive fashion. Due to the
heterogeneity of the data and the diversity of the clinical trial
designs, no additional subanalyses or meta-analyses were planned
or performed.
Terms such as “on waking”, “early morning”, “later in the
morning”, and “morning” were all used in the identified articles;
data related to these time points are discussed together in this
review as “morning” symptoms, although the exact descriptions
used in the source material are used wherever possible. With
regards to descriptions of symptoms, the terminology used in the
original source materials varied significantly; therefore, to simplify
the reading of this review, standardized terms are used through-
out. A glossary of these standardized terms is provided in Table 2.
RESULTS
Trial flow
A total of 544 articles were identified by the initial searches (Fig. 1).
After the first screening and removal of any duplicates, 255 full-
text articles were selected for review. Following the second
screening, 33 articles met the inclusion criteria. Thirteen additional
articles eligible for inclusion were identified by manual searches of
reference lists and bibliographies. An additional ten studies were
included to capture literature published since the initial search,
leading to a total of 56 articles.
Trial characteristics and participants
Of the 56 articles included in the descriptive data analysis, 28
articles reported on randomized controlled trials, either in the
form of primary data publication or in relation to subgroup,
secondary, or pooled analyses. The remaining publications
detailed result from a variety of studies, including cross-sectional,
observational studies, noninterventional trials, survey- or
interview-based assessments, or secondary analyses from existing
Table 1. Study selection criteria.
Criteriaa
Patient • Adult patients (>40 years) of any gender or race, with a diagnosis of COPD (any disease severity) and having daytime COPD symptoms
• Studies enrolling a mixed population of patients experiencing daytime and night-time symptoms were only included if subgroup
data for patients with daytime symptoms were available
Intervention • No selection criteria
Comparator • No selection criteria
Outcome • Primary outcomes of interest included: prevalence of daytime COPD symptoms; relative bothersomeness/troublesomeness or
intensity of symptoms; how the prevalence and bothersomeness/troublesomeness or intensity fluctuates throughout the day;
relationship between daytime COPD symptoms and other outcomes, such as activities of daily living, health status, quality of life, and
exacerbations; types of interventions used to treat daytime symptoms, including pharmacotherapy; and measures and tools used to
assess daytime COPD symptoms
Study design • All studies reporting any data on daytime COPD symptoms (e.g., multi- and single-center randomized controlled trials,
nonrandomized trials, single-arm clinical trials, and real-world and observational studies)
• Studies with full-text publications available only in languages other than English were excluded
COPD chronic obstructive pulmonary disease.
aCriteria were in line with Patient, Intervention, Comparator, Outcomes and Study Design (PICOS).
Table 2. Glossary of standardized terms used in review article.
Standardized term Alternative terms used in literature
Morning symptoms • Symptoms on waking
• Early morning symptoms
• Symptoms later in the morning
Breathlessness • Dyspnea (or dyspnea)
• Shortness of breath
Cough • Coughing
• Increased cough
• Persistent/recurring cough (±ing)





• Increased sputum/mucus production
• Coughing up phlegm
• Bringing up phlegm or mucus
• Difficulty bringing up phlegm
Wheezing • Increased wheezing
• Wheezing or grunting
Chest tightness • Tightness of the chest
• Tightness in the chest
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real-world databases. Across the studies and analyses identified,
data were presented on an estimated 40,000 patients with COPD
(although some of these patients may have participated in more
than one trial and/or analysis).
Daytime COPD symptoms: prevalence, variability, and burden
Information on the prevalence (number of patients reporting
symptoms) of common daytime symptoms of COPD was collated
from 18 articles that had extractable data (Supplementary
Table 4).2,4,12,14–16,23–34 In nine articles, the relative prevalence
rates of COPD symptoms (both for all symptoms and for individual
symptoms) were generally higher in the morning and/or daytime
(when defined, this was usually the time between the morning
period and when the patient goes to bed) compared with at night
(Supplementary Table 4).4,16,23,28–30,32–34 For example, a preva-
lence of 81.4% for morning symptoms and 63.0% for night-time
symptoms was reported by Miravitlles et al.4 Similar trends of
morning and/or daytime versus night-time symptom prevalence
were reported by Bateman et al.23 (94.4 versus 88.3%), Marth
et al.28 (91.7 versus 70.6%), Soler-Cataluna et al.29 (71.3–83.5%
versus 59.0–63.8%), Stephenson et al.30 (67.3 versus 50.0% of those
completing the survey), Tsiligianni et al.16 (51.9 versus 39.4%), and
Miravitlles et al.33 (71 versus 48%). Moreover, where prevalence rates
were provided separately for morning and daytime, they were
usually relatively similar.4,26,29,32 However, one study based on
physician reports (not patient self-reporting) went against this
trend.15 In this study by Roche et al., physicians reported morning
symptoms for only 40% of their patients with COPD, compared with
daytime symptoms for 97% of patients and night-time symptoms for
58% of patients. Breathlessness, cough, and increased sputum
usually made up the top three most prevalent COPD symptoms
reported for both morning and daytime, though relative proportions
varied based on differences in populations and study designs
(Supplementary Table 4).4,12,14,23–27,29,30 Wheezing and chest tight-
ness/congestion were usually less commonly reported for morning
and daytime.
Variability (variation in symptom prevalence across a 24-h
period) of common daytime symptoms of COPD were reported in
ten articles (Supplementary Table 4).4,13–16,23,26,28–30 Accumulated
evidence from nine of these articles indicates that the prevalence
of COPD symptoms tends to fluctuate over the course of the
day.4,14–16,23,26,28–30 This is also demonstrated in a large study by
Kessler et al.,13 where 44.7% of symptomatic patients perceived
variability in one or more of their COPD symptoms throughout the
day, with breathlessness and chest tightness varying the most. In
three articles, the patients were asked about the variability of
symptoms at different times of the day and night based on the
perceived severity. Two articles found that a similar proportion of
patients reported moderate to very severe symptoms in the
morning, during the daytime, and at night.4,30 In the third study,
more patients reported “at least moderate” symptoms in the
morning than at night.28
A number of studies have described the fluctuation in
symptomatic burden (bothersomeness and/or intensity of
Fig. 1 PRISMA trial flow diagram. COPD chronic obstructive pulmonary disease.
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symptoms throughout the day) by asking respondents what time
of day their symptoms were most troublesome, bothersome,
distressing, or intense (a summary of the articles with extractable
data is provided in Supplementary Table 5). Based on the
combined findings of seven articles, the burden of COPD
symptoms appears to be greatest in the morning.12,13,17,25,27,35,36
In a survey-based study by Decramer et al.,35 for example, 73% of
reported respiratory symptoms were “most intense” in the
morning, compared with 14% in the evening. In a large
observational study, Partridge et al.12 similarly found that
symptoms were “worse than usual” in the morning for 37% of
study patients, versus 21% in the evening. Conversely, when
Worth et al.37 analyzed data from almost 6000 patients entering
the German DACCORD study, they found that a greater
percentage of patients indicated symptoms were most bother-
some during the daytime (56%) than in the morning (33%). In four
articles where the day was broken down into shorter time
categories (e.g., “morning”, “midday/noon”, “afternoon”, “eve-
ning”), there was a trend for the greatest symptom burden
occurring in the morning period.12,13,25,36 Moreover, in the articles
reporting on differences in symptom burden at different stages of
the morning, there was a clear trend for the greatest impact
occurring on waking, before tapering off slightly later in the
morning.13,25 Partridge et al.12 reported that 37% of all the studied
patients with COPD and 59% of patients with severe COPD were
awoken by their symptoms in the morning at least 3 days a week.
Three of the analyzed articles reported on specific respiratory
symptoms as an outcome:13,25,27 in all three, “morning” was the
time of greatest burden from breathlessness, cough, and
increased sputum, with a clear tapering off of these symptoms
during the remainder of the day. Cough, for example, was
reported by Kessler et al.13 as “most troublesome” upon waking/
later in the morning in 49%/22% of study participants, compared
with 15% in the afternoon and 19% in the evening. In the study by
Kim et al.,25 cough was “most troublesome” upon waking/in the
morning for 39%/33% of the patients who reported COPD
symptoms, versus 16% in the afternoon and 7% in the evening;
and in the Turkish COPD-SUNRISE observational study by Kuyucu
et al.,27 54% of participants reported cough as “most severe” in the
morning, compared with 28% in the daytime. The trend for
wheezing was less consistent among the identified studies. More
patients in the studies by Kim et al.25 and Kessler et al.13 reported
wheezing as “most troublesome” upon waking/later in the
morning (62%/13% and 31%/22%, respectively), compared with
the afternoon (17 and 18%) and evening (5 and 26%); however, in
the Kuyucu et al.27 study, a similar proportion of patients reported
wheezing as “most severe” in the daytime (33%) and in the
morning (31%).27 Similar inconsistencies were seen for the pattern
of burden for chest tightness. It is noteworthy, however, that when
comparing the burden of symptoms at a specific time point,
wheezing and chest tightness were usually the most burdensome
symptoms in the afternoon, evening, and night, whereas breath-
lessness, cough, and increased sputum were usually the most
burdensome symptoms on waking or in the morning (Supple-
mentary Table 5).
Daytime COPD symptoms: impact on other outcomes in daily life
In 13 articles, it was reported that daytime COPD symptoms had a
negative impact on patients’ ability to perform normal daily
activities (Supplementary Table 6).4,12,13,15,17,24,25,27,28,30,35,36,38 This
was most notable in terms of morning activities, with five articles
reporting that activities such as getting up/getting out of bed,
personal hygiene (e.g., showering), and dressing were particularly
impacted.12,13,25,27,36 For example, in a cross-sectional observa-
tional study of 472 COPD patients, Espinosa de los Monteros
et al.36 found that 27% of patients had some type of impediment
getting out of bed, and 29% and 33% had difficulties with
personal hygiene and getting dressed, respectively. Moreover,
morning or daytime “physical” activities (e.g., going up and down
stairs, performing household chores, or doing exercise/sports)
were also severely impacted.12,13,17,24,27 Although it was only
reported in two articles related to survey-/interview-based studies,
breathlessness was most commonly identified as the cause of
patients’ reduced ability to perform normal daily activities.12,17
It is perhaps not surprising that in the studies where a relevant
enquiry was made, a large proportion of patients indicated that
they had altered their morning routine to accommodate their
reduced ability to perform their normal activities, nor is it
unexpected that patients ranked having well-controlled symp-
toms all day as the most important treatment attribute.12,17,30,39
Data from seven studies on the effects of daytime COPD
symptoms on health status and/or QOL showed that there were
raised levels of anxiety, depression, distress, and social inhibition/
embarrassment among patients (Supplementary Table
6).4,12,15,17,29,30,35 Stephenson et al.,30 for example, noted that
54% of study patients with early morning symptoms reported
feeling anxious (slightly to extremely), whereas O’Hagan and
Chavannes17 found that 53% of surveyed participants had
experienced social inhibition or embarrassment because of their
morning symptoms. Of note, this relationship was based not only
on subjective patient/physician reporting, but also on scores from
validated measures, e.g., the COPD Assessment Tool (CAT), Clinical
COPD Questionnaire (CCQ), Hospital, Anxiety and Depression Scale
(HADS), and EuroQol Five Dimensions Questionnaire (EQ-5D).
Articles from both Miravitlles et al. and Soler-Cataluna et al.
reported significantly worse outcomes in terms of health status
(CAT scores) and anxiety or depression (HADS scores) in patients
with morning and daytime symptoms versus those without
symptoms, whereas Roche et al. found that patients with morning
symptoms had significantly worse CAT and EQ-5D scores than
those without morning symptoms.4,15 Moreover, two articles
reporting on the same study also noted a relationship between
morning and daytime COPD symptoms and poor sleep quality,
based on higher COPD and Asthma Sleep Impact Scale (CASIS)
scores for patients with morning and daytime symptoms versus
patients with no symptoms.4,29
In this review, four articles reported on the relationship between
daytime COPD symptoms and exacerbations.14–16,33 In one,
describing data from a large, cross-sectional, observational study,
Tsiligianni et al.16 noted no statistically significant association
between morning COPD symptoms and the likelihood of
exacerbations 10–17 months after the baseline visit; this was
based on logistic regression models. Similarly, in another large
observational study, Miravitlles et al.14 showed that the presence
of early morning or daytime symptoms were not independent
predictors of exacerbations during the 6 months following
baseline in a logistic regression model. Interestingly, in the two
articles assessing the relationship between symptoms and a
history of exacerbations (all based on large-scale, observational/
real-world datasets), the presence of morning or daytime COPD
symptoms was strongly associated with a higher frequency of
exacerbations in the preceding 12 months.14,15 Another study by
Miravitlles et al.33 found that any type of symptom variability was
significantly associated with more exacerbations in the
previous year.
The impact of COPD symptoms on other aspects of patients’
lives further emphasizes the overall burden of the disease. For
example, O’Hagan and Chavannes17 noted that 63% of respon-
dents in their study claimed that morning COPD symptoms had a
negative impact on their working day. Roche et al. showed that
patients in paid employment with morning symptoms had
significantly more problems getting up and ready for the day,
and had significantly more days off work in the 12 months prior to
the study, compared with patients with COPD without morning
symptoms. Miravitlles et al.14 have also shown significant
I Tsiligianni and JWH Kocks
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relationships between both early morning and daytime symptoms
and visits to the family doctor during a 6-month follow-up period,
and between daytime COPD symptoms and visits to a specialist.
Taken together, these results suggest that morning and daytime
COPD symptoms could have serious financial implications for both
the affected patient (through potential loss of earnings) and
healthcare systems (through potential increased resource use).
Daytime COPD symptoms: impact of interventions
Twenty-eight articles in this review looked specifically at the
effects of interventions on daytime symptoms of COPD (Supple-
mentary Table 7).23,28,40–65 These articles related to clinical studies
of pharmacotherapy for COPD, and included evaluations of short-
acting muscarinic antagonists (SAMA; ipratropium), long-acting
muscarinic antagonists (LAMA; aclidinium, glycopyrronium, tio-
tropium), short-acting β2-agonists (SABA; albuterol, salbutamol),
long-acting β2-agonists (LABA; indacaterol, formoterol, salme-
terol), and inhaled corticosteroids (ICS; fluticasone, budesonide),
either alone or in different combinations. Eighteen articles
reported on placebo-controlled studies; 17 articles showed that
the tested active therapies/combinations provided statistically
significant improvements in daytime symptomatology compared
with placebo23,40,42,44,46–51,54,56–59,61,64 and one study reported
significant improvement in 24-h lung function with twice-daily
LAMA/LABA compared with placebo.65 Combinations consisting of
LAMA/LABA (±ICS) tended to improve daytime symptoms more
effectively than either LABA or LAMA monotherapy.23,54,56,59,61
Many of these studies also reported benefits of pharmacotherapy
on patients’ abilities to function normally, which generally
manifested as an increase in the number of days that the patient
could perform usual daily activities.23,40,42,44,47,49–51,54,59,61 One
other article comprised a single-arm study of LAMA therapy in
patients with COPD and reported significant reductions versus
baseline in the severity of early morning symptoms, and hence in
difficulties in performing morning activities.28 Eight articles
looking at the impact of pharmacotherapy on daytime symptoms
of COPD involved non-placebo-controlled head-to-head compar-
isons.41,43,45,52,53,55,60,63 Drug combinations including long-acting
bronchodilators (LABA+ ICS41,43,52 or LABA+ SAMA45) were more
effective than short-acting combinations (SABA+ SAMA) at
improving daytime symptom scores. In a study by Vogelmeier
et al.,60 a LAMA/LABA combination significantly improved the
number of symptom-free days and daytime breathlessness scores
of patients with COPD when compared with a LABA+ ICS
combination; however, overall reductions in patient symptom
scores were not significantly different between the two regimens.
The findings of these pharmacologic studies are somewhat
aligned with patient expectations of COPD treatments. Indeed,
O’Hagan and Chavannes17 showed that 79% of patients agreed
that their medication helps with their morning symptoms; more
than half of patients stated that their medication helps their
breathing, reduces shortness of breath, and improves their cough.
However, only 21% said their medication improves their ability to
carry out morning activities.
Daytime COPD symptoms: measures and tools
The measures/tools used in the included articles varied widely
(Supplementary Tables 4–5), and not all were validated for use in
patients with COPD. The clinical trials we identified (Supplemen-
tary Table 7) tended to use a somewhat consistent selection of
measures/tools. The validated Evaluating Respiratory Symptoms
(E-RS) in COPD questionnaire was the most frequently used.66
Several articles described the development and validation of new
measures/tools for specifically assessing daytime COPD symp-
toms. Mocarski et al.67 reported on the Early Morning Symptoms
of COPD Instrument (EMSCI); Partridge et al.68 on the Capacity of
Daily Living during the Morning (CDLM) questionnaire; Garrow
et al.69 on the Manchester Early Morning Symptom Index (MEMSI);
and Globe et al.24 on the COPD Morning Symptom Diary (COPD-
MSD). One article explained the importance of a daily versus a
weekly diary for capturing daily fluctuations in COPD symptoms.70
A further detailed analysis of the measures and tools used to
assess the prevalence and burden of daytime symptoms, however,
was beyond the scope of this literature review.
DISCUSSION
Summary of key findings
This systematic review and literature analysis identified 56 articles
reporting daytime COPD symptoms. Taken together, the accumu-
lated evidence demonstrates that the symptomatic burden of
COPD appears to be most acute in the morning, particularly at the
time of waking. The prevalence of COPD symptoms tends to
fluctuate over the course of the day, and is generally higher in the
morning and/or daytime compared with at night. These morning
symptoms have a substantial impact on patients’ ability to
function normally (both in the morning and through the
remainder of the day) and negatively affect patients’ QoL and
health status. The literature confirms that pharmacotherapy can
help patients to function normally during the day. Additionally,
our analysis showed that the measures and tools used to evaluate
daytime COPD symptoms are not uniform and vary widely across
studies. We propose that there is need for a validated tool to
better assess COPD symptoms, particularly morning symptoms.71
Variability in daytime COPD symptoms
The literature searches we conducted revealed a pattern of
daytime symptomatology for patients with COPD. All character-
istic symptoms (breathlessness, cough, increased sputum) and
some of the associated symptoms (wheezing and chest tightness/
congestion) are most prevalent and/or burdensome upon waking,
with a gradual tapering off through the remainder of the morning
and through lunchtime, before wheezing and chest tightness/
congestion become prevalent and/or burdensome again in the
afternoon or evening and into the night (Fig. 2). In another recent
review, Singh et al.72 concluded that COPD symptoms are
troublesome, variable, and can occur at any time during a 24-h
period.
Burden of daytime COPD symptoms
The literature showed a clear trend for the greatest burden from
COPD occurring in the morning. This is perhaps an area that needs
increased attention from both general practitioners and respira-
tory specialists. Indeed, Partridge et al.12 showed, via quantitative
Internet interviews of >800 patients with COPD across multiple
countries, that only 22–44% reported being asked by their
physician whether they experience symptoms in the morning,
and only 9–22% said they had been asked how they manage their
morning routines. It should be noted that the article by Partridge
et al. was published 10 years ago; however, there remains a strong
argument for treating physicians to discuss with their patients
with COPD when their symptoms are most troublesome and how
this can be best managed.
Negative impact of daytime COPD symptoms on QoL
This literature review showed that daytime COPD symptoms can
negatively impact the lives of affected patients. This is demon-
strated by the reduced ability to perform normal daily activities
(e.g., going up and down stairs, household chores, shopping), as
well as worsened QoL and health status (including increased
anxiety/depression) and social embarrassment. It can also be
surmised that, through their association with work-related issues
(increased absenteeism) and increased medical resource use
I Tsiligianni and JWH Kocks
5
Published in partnership with Primary Care Respiratory Society UK npj Primary Care Respiratory Medicine (2020)     6 
(higher numbers of physician/specialist/hospital visits), these
daytime symptoms may also have the potential to cause a serious
financial impact for both patients and healthcare services. These
observations further emphasize the need for healthcare profes-
sionals to focus on patients’ morning symptoms and routines.
Other support mechanisms (e.g., pulmonary rehabilitation pro-
grams) should also ensure that there is a similar specific focus on
morning activities.
Therapeutic options and their impact on daytime COPD symptoms
Many therapeutic options are available for the treatment of COPD,
as identified in this literature review. They have the potential to
mitigate daytime symptoms and can help patients function
normally. Few studies specifically report on the effects of
pharmacologic interventions on daytime or morning symptoms.
Furthermore, O’Hagan and Chavannes17 showed that while the
majority of patients agreed that medication improved their
morning symptoms, this did not necessarily translate into an
increased ability to carry out morning/daily activities. These
observations point to a need for novel clinical studies that
prospectively assess the various different medication classes,
treatment combinations, and treatment regimens (e.g., once
versus twice-daily) for their impact on daytime symptoms and
the patients’ ability to function normally. The findings also support
the continued search for newer interventions that may be even
better suited to address this medical need. In addition, because
the characteristic symptoms of COPD (breathlessness, cough,
increased sputum) are particularly prevalent in the morning,
future studies could also specifically assess which interventions
may help patients manage these symptoms, and whether they are
pharmacologic in nature or not (e.g., breathing exercises or
pulmonary rehabilitation). It is argued that in order to truly ensure
effective patient-orientated care in COPD, patients should be
evaluated on the basis of lung function, frequency of symptoms,
and the impact of symptoms on their QoL. Current COPD
treatment decisions (selection of LAMA monotherapy, combina-
tion therapy with LAMA/LABA, or add-on therapy with LAMA to
LABA/ICS) should be based on individualized assessment, ensuring
personalization to the particular needs of the patient.72,73
Tools and measures to assess daytime COPD symptoms
Many different tools have been used to measure and assess
daytime symptoms of COPD, not all of which are validated for use
in patients with the condition, or specific or focused enough to
truly elicit the required information. The E-RS questionnaire, for
example, is validated for use in COPD, and was used frequently in
the identified clinical studies. This questionnaire is completed in
the evening, and refers the end-user back to their experiences that
“day”. However, depending on the end-user’s personal interpreta-
tion, that could mean they record the symptoms experienced
since they awoke or, alternatively, the symptoms experienced
since they completed the questionnaire the evening before
(which would incorporate their night-time experiences). Similarly,
one study reported on the prevalence of daytime sleepiness using
Fig. 2 Daytime COPD symptoms.
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results from the Epworth Sleepiness Scale.2 However, this scale is
based upon a questionnaire that records the self-reported level of
sleepiness; it does not collect information on the cause of that
sleepiness.74 Indeed, since studies have commented on the close
association between COPD and sleep disorders, such as insomnia
and sleep apnea,2,75 the relationship between daytime COPD
symptoms and daytime sleepiness is particularly complex. More
focused and validated tools (e.g., the EMSCI, CDLM, MEMSI, and
COPD-MSD) have been developed to specifically assess morning
COPD symptoms and their secondary effects,24,67–69 but do not
appear to be widely utilized to date. Additionally, there were two
study design papers that describe the methodology of new
studies in patients with COPD: STORICO, an observational study
which aims to describe the frequency and evolution of early
morning, daytime, and night-time COPD symptoms using clinically
defined phenotypes; and FAntasTIGUE, a multicenter, longitudinal
observational study which aims to assess severity and day-to-day/
diurnal variations in fatigue.76,77 Once data are available, these
studies will hopefully further help to determine frequency and
changes in COPD-associated symptoms and fatigue.
Strengths and limitations
The strengths of this systematic review include its broad search
criteria and inclusive nature, with no date restrictions. Never-
theless, there are also several limitations that should be
considered in relation to the interpretation of the findings. For
example, for many of the identified articles, the data were
extracted from observational studies or survey-/interview-based
evaluations, which are inherently limited by their reliance on
patient self-reporting. In some studies, symptom prevalence may
not have been 100%, even though GOLD criteria for COPD
diagnosis states that all patients must be symptomatic; this could
again be attributable to patient self-reporting and variability in the
type of survey questions.1 There was also considerable hetero-
geneity in multiple aspects of the study design, with no additional
meta-analysis methodology used to account for this. In addition,
as evidenced by the findings of this review, the manner in which
daytime COPD symptoms were assessed varied widely, which
could have influenced the trends and patterns observed. It is
noteworthy, however, that these limitations relate to the evidence
sources rather than the systematic review methodology.
Overall, the results of this study show that COPD symptoms are
at their worst in the morning, particularly upon waking. These
symptoms have a substantial impact on the ability of patients to
function normally throughout the day, and they worsen patients’
quality of life. However, there are several treatments for COPD that
can help reduce these symptoms. Physicians should initiate
discussions with their patients regarding the time of day they
suffer with symptoms the most, and adapt their clinical approach
accordingly. In addition, the abundance of data reviewed suggests
a need for: (1) a better understanding of how COPD symptoms
(particularly morning symptoms) impact patient daily functioning,
which could lead to better management approaches; (2) more
studies specifically evaluating symptoms at well-defined periods
throughout the day, using validated tools and measures; and (3) a
consistent approach to measuring daytime symptoms and their
impact on daily functioning.
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